Viatris (NASDAQ:VTRS) Reports Q4 CY2025 Revenue Surpassing Expectations

Viatris (VTRS) Surpasses Q4 2025 Revenue Expectations

Viatris (NASDAQ:VTRS), a global pharmaceutical company, posted fourth-quarter 2025 revenue that exceeded analyst forecasts, with sales rising 5% year-over-year to reach $3.7 billion. The company’s guidance for full-year revenue sits at $14.7 billion (midpoint), which is 2.3% higher than what Wall Street anticipated. Adjusted earnings per share (non-GAAP) came in at $0.57, beating consensus estimates by 7.4%.

Should You Consider Buying Viatris?

Q4 2025 Financial Highlights

• Revenue: $3.7 billion, outperforming the $3.52 billion estimate (5% annual growth, 5.3% above expectations)
• Adjusted EPS: $0.57, compared to the $0.53 estimate (7.4% above expectations)
• Adjusted EBITDA: $1 billion, topping the $950 million estimate (27.1% margin, 5.6% beat)
• 2026 Adjusted EPS Guidance: $2.40 (midpoint), which is 3.8% below analyst projections
• 2026 EBITDA Guidance: $4.3 billion (midpoint), matching analyst expectations
• Operating Margin: -5.2%, unchanged from the same period last year
• Free Cash Flow Margin: 16.7%, up from 9.7% a year ago
• Market Cap: $18.52 billion

About Viatris

Formed in 2020 through the merger of Mylan and Pfizer’s Upjohn division, Viatris is a healthcare company specializing in the development, production, and distribution of both branded and generic medications. The company operates in over 165 countries worldwide.

Revenue Trends

Evaluating a company’s long-term sales growth helps gauge its overall strength. While any business can have a few strong quarters, sustained growth over several years is a sign of quality. Over the past five years, Viatris’s annualized revenue growth was just 3.7%, which is considered modest for the healthcare sector and falls short of industry benchmarks.

Although long-term growth is crucial, shorter-term trends can reveal shifts in innovation or market demand. Viatris saw revenue gains in previous years, but over the past two years, annual revenue has declined by 3.7%.

For the latest quarter, Viatris achieved 5% year-over-year revenue growth, surpassing analyst expectations by 5.3%.

Looking forward, analysts predict that Viatris’s revenue will remain steady over the next year. While new products and services may drive future growth, these projections still lag behind the healthcare sector average.

Many industry leaders, such as Microsoft and Coca-Cola, started as lesser-known growth stories. We’ve identified a promising AI semiconductor company that Wall Street may be overlooking.

Profitability and Margins

Operating Margin

Over the past five years, Viatris’s average quarterly operating profit hovered around breakeven, which is not ideal for a healthcare company. The operating margin has dropped by 18.4 percentage points during this period, with a sharper decline of 23.6 points in the last two years. This suggests rising costs that the company has been unable to offset through pricing power.

This quarter, Viatris reported an operating margin of -5.2%, continuing its trend of weak profitability.

Earnings Per Share (EPS) Analysis

Tracking long-term changes in EPS helps determine whether a company’s growth is translating into profits. For Viatris, EPS has fallen at an average rate of 9.8% per year over the past five years, even as revenue grew modestly. Despite this, operating margins improved, indicating that factors like interest expenses and taxes have weighed on net earnings.

Further analysis shows that Viatris’s share count increased by 34.9% over five years, diluting existing shareholders and reflecting less efficient management of operating expenses.

In the fourth quarter, adjusted EPS reached $0.57, up from $0.54 a year earlier and 7.4% above analyst expectations. Wall Street anticipates full-year EPS of $2.36 for the next 12 months, representing a 5.4% increase.

Summary of Q4 Results

Viatris delivered a strong revenue beat this quarter and issued full-year guidance that surpassed analyst expectations. However, its EPS outlook fell short. Overall, the results were mixed, and the stock price remained steady at $15.93 following the announcement.

Is Viatris a good investment at this time? When evaluating the company, it’s important to consider its valuation, business fundamentals, and recent performance.